A case of denosumab-associated hyperparathyroidism: A differential diagnostic challenge
2021 ◽
pp. 024-025
Keyword(s):
Denosumab is a relatively new medicine that has become the second option in the treatment of biphosphonate-resistant or intolerant osteoporosis. Subcutaneous injection with 6-month intervals, approval of its usage in stage 3-4 CKD and not having gastrointestinal side effects are advantages of denosumab. However, it has some disadvantages like requiring monitoring serum levels of calcium and vitamin D before each injection.
2015 ◽
Vol 93
(1)
◽
pp. 53-61
◽
Keyword(s):
2014 ◽
Vol 84
(1-2)
◽
pp. 27-34
◽
Keyword(s):
2020 ◽
1979 ◽
2019 ◽
Vol 50
(4)
◽
pp. 217-221
Keyword(s):
2019 ◽
Vol 17
(6)
◽
pp. 610-617
◽